Ads
related to: field fenofibrate study for prostate cancer- Side Effect Information
Learn More About Potential Side
Effects And Safety Information.
- Oral Medication
Learn More About An Oral Treatment
For Metastatic Prostate Cancer.
- Real Patient Story
Learn How A Patient's BRCA Status
Informed His Treatment Journey.
- Clinical Study Data
Find Clinical Study Data
At The Patient Site.
- Side Effect Information
Search results
Results From The WOW.Com Content Network
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) is a clinical trial investigating treatments for high risk or terminal prostate cancer. Recruitment started in 2005 and ended in 2022; as of January 2020, over 10,000 participants had joined the trial.
Field cancerization or field effect (also termed field change, field change cancerization, field carcinogenesis, cancer field effect or premalignant field defect) is a biological process in which large areas of cells at a tissue surface or within an organ are affected by carcinogenic alterations. The process arises from exposure to an injurious ...
The FIELD study reported that fenofibrate at doses of 200 mg daily, reduced the risk for any amputation by 37% independent of glycaemic control, presence or absence of dyslipidaemia and its lipid-lowering mechanism of action.
Rosalind Anne Eeles is a Professor of Oncogenetics at the Institute of Cancer Research and clinician at the Royal Marsden NHS Foundation Trust.She is a leader in the field of genetic susceptibility to prostate cancer, and is known for the discovery of 14 genetic variants involved in prostate cancer predisposition. [1]
[8] [9] Low, along with Timothy Ratliff and Tom Gardner, is credited with the development of the prostate cancer drug Pluvicto, which was granted breakthrough status by the Food and Drug Administration in 2021. [10] In the late 1990s, Low cofounded, with Christopher Leamon, biotechnology company Endocyte where he served as chief science officer ...
She is a co-author of a study published in 2024 that found unreliable pulse oximeter readings might limit the way Black patients with heart failure qualify for those potentially lifesaving procedures.